Combined HIV prevention medicine and doxycycline after sex to prevent infections in young men
Tests HIV PrEP together with doxycycline after sex in young men.
Plain-language title generated from the registry record
Registry title: Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
Key facts
- Where
- Los Angeles and The Bronx, United StatesSee the 2 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 29 years old?
Source: NCT07658976, who can take part
Where in United States
- UCLA Vine Street ClinicLos Angeles, United StatesNo longer taking part
- Bronx Prevention Research Center CRSThe Bronx, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- HIV Prevention Trials Network
- Trial code
- NCT07658976
- Record updated
- 22 June 2026
- Original description
Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young MenRead full original descriptionShow less
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV PrEP and STI PEP for Young Men
Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men
Inclusion: Men ages 18 - 29 years; Men who are in communities most affected by the HIV epidemic; Willing and able to provide informed consent; Reports having anal sex with men in the last 6 months; Have certain risk factors for HIV acquisition, defined as any of the following in the past 6 months:; Any condomless anal sex with a man; not including within a monogamous relationship with an HIV-negative partner or an HIV-positive partner who is virally suppressed; Reporting 2 or more male partners, regardless of condom use; Reporting gonorrhea, chlamydia, or syphilis diagnosis; Any stimulant use (e.g., cocaine, amphetamines); Not on PrEP within the past 3 months due to participant choice; Interested in learning more about PrEP or starting PrEP; No evidence of HIV infection at Screening and Enrollment, based on the HIV testing algorithm; Owns an iOS or Android mobile phone and able to successfully download mobile apps and send and receive text messages; Must not share the mobile phone used for their participation in the study; Able to read and write.
Exclusion: Currently participating in another interventional trial of PrEP agents, or prior enrollment in studies of long-acting PrEP, including HPTN 083; Currently on doxycycline for STI PEP; Prior diagnosis of HIV infection; Tetracycline allergy; Reactive HIV rapid test at Screening or reactive HIV Ag/Ab rapid test at Enrollment, regardless of subsequent HIV test results; Any other condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives would make the patient unsuitable for the study or unable/unwilling to comply with the study requirements; Participated in HPTN 113-01; Plans to move away from the study area within the next year; Has ever used CAB-LA or other long-acting PrEP agent.